Shanghai Fosun Pharmaceutical (02196): Multiple products newly included in the National Reimbursement Drug List
Shanghai Fosun Pharmaceutical (02196) announced that, according to the "National Drug List for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2026)" issued on November 14, 2026 by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, multiple marketed products of the group have been included for the first time, had remarks-related information adjusted, or been transferred from negotiated drugs to routine list management.
Shanghai Fosun Pharmaceutical (02196) announced that, according to the "National Drug List for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2026)" released on November 14, 2026 by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, multiple marketed products of the Group have been included for the first time, have had remarks-related information adjusted, or have been transferred from negotiated drugs to routine list management.
I. Main varieties newly included or with remarks-related information adjusted
II. Main varieties transferred from negotiated drugs to routine list management
Related Articles

BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.

Guangdong Shenling Environmental Systems (301018.SZ) plans to participate in bidding for land use rights to meet its development needs in the liquid cooling and temperature control field.

INNOVENT BIO (01801): Sintilimab ZYBRIVO receives positive CHMP opinion recommending approval for first-line treatment of non-squamous non-small cell lung cancer
BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.

Guangdong Shenling Environmental Systems (301018.SZ) plans to participate in bidding for land use rights to meet its development needs in the liquid cooling and temperature control field.

INNOVENT BIO (01801): Sintilimab ZYBRIVO receives positive CHMP opinion recommending approval for first-line treatment of non-squamous non-small cell lung cancer






